Skip to main content
. 2021 May 4;41(5):BSR20203362. doi: 10.1042/BSR20203362

Figure 6. The identification of primary podocytes and the selection of the optimal puromycin concentration.

Figure 6

(A) The identification of primary podocytes by immunofluorescence. (B) The selection of puromycin concentration and treatment duration based on CCK8 assay. (C) The IC50 of puromycin at the 8, 24, and 48 h time points. Compared with the control group, *P<0.05.